No Interactions Between New Schizophrenia Treatment and Common SSRI

Armen Hareyan's picture
Advertisement

Schizophrenia treatment research

A new study presented at the 160th Annual Meeting of the American Psychiatric Association shows that paroxetine, a selective serotonin reuptake inhibitor (SSRI) often prescribed for depression and known to interact with several antipsychotic medications, produced no significant drug interaction with paliperidone extended-release (ER). Approximately 50 percent of patients with schizophrenia have at least one other psychiatric or medical condition requiring medication, most commonly depression.

Advertisement